|
Patent landscape, scope, and claims: |
US Patent 6,919,092: Scope, Claims, and Patent Landscape Analysis
What is the scope of US Patent 6,919,092?
US Patent 6,919,092 is titled "Methods for treating or preventing osteoporosis by administration of calcitonin analogs." It covers specific peptide analogs related to human calcitonin, designed to treat calcium disorders, particularly osteoporosis. The patent claims include compositions and methods involving these analogs, emphasizing their use in lowering blood calcium levels and increasing bone mineral density.
The patent broadly protects:
- Peptides with amino acid sequences that replicate or modify human calcitonin.
- Methods of manufacturing such peptides.
- Therapeutic methods involving administering these peptides to treat osteoporosis, hypercalcemia, and related calcium metabolic disorders.
The patent's scope centers on peptides with particular amino acid substitutions conferring enhanced stability or activity, and their therapeutic uses.
What are the key claims of US Patent 6,919,092?
Primary claims overview:
-
Claim 1: A peptide comprising an amino acid sequence substantially similar to human calcitonin, with specific substitutions at key positions to enhance stability and activity.
-
Claims 2-10: Variations of Claim 1, specifying different amino acid substitutions or modifications, such as amino acid replacements at positions 10, 15, or 22, intended to improve pharmacokinetics or reduce immunogenicity.
-
Claim 11: A pharmaceutical composition comprising the peptide of claims 1-10 and a pharmaceutically acceptable carrier.
-
Claims 12-15: Methods of treatment using the peptide to treat osteoporosis or hypercalcemia.
-
Claims 16-20: Methods of manufacturing the peptide, including synthesis and formulation.
Claim specifics:
- Peptides with amino acid substitutions at positions 10 (e.g., proline for methionine), position 15 (e.g., serine for leucine), and position 22 (e.g., threonine for alanine).
- Peptides designed to have improved half-life or activity compared to natural calcitonin.
- Administration methods include injections and other delivery modes suitable for clinical use.
Limitations:
Claims focus on analogs with specific amino acid changes, excluding broader classes of peptides without these modifications. The claims are centered on peptides that are "substantially similar" but incorporate structural modifications for improved therapeutic benefits.
What is the patent landscape surrounding US Patent 6,919,092?
Key related patents and prior art:
- US Patent 5,733,876: Focused on calcitonin peptides for osteoporosis, predating the 2000 filing date of the '092 patent.
- WO 98/07104: International application covering calcitonin analogs with similar amino acid modifications.
- EP 1,252,987: European patent also covering calcitonin-related peptides with enhanced stability.
- US Patent 6,444,694: Discloses calcitonin analogs with amino acid substitutions aimed at modulating activity.
Patent family and continuation applications:
- The patent family includes related patents and patent applications that claim narrow and broad variations of calcitonin analogs.
- Several continuation-in-part applications expand claims to include newer analogs and formulations.
Patent expiration and freedom to operate:
- The patent was filed in 2000 and issued in 2005, with a typical 20-year term extending to 2025, subject to maintenance fees.
- As of 2023, the patent is nearing expiration, opening potential for generic developers or biosimilar entrants.
Litigation and licensing activity:
- No known litigation specifically targeting US patent 6,919,092.
- Licensing agreements involve pharma companies seeking to develop calcitonin-based therapeutics, often citing this patent.
Industry positioning:
- Patent protects key peptide modifications used in marketed calcitonin drugs, such as Miacalcin (calcitonin-salmon).
- Any development of new analogs with similar amino acid substitutions builds upon or risks infringing this patent if overlapping claims are present.
Key differences from prior art:
- Focus on specific amino acid substitutions at positions 10, 15, and 22.
- Emphasis on improved pharmacokinetics and stability.
- Extends claims to methods of synthesis, formulation, and therapeutic use.
Conclusion: Impact on R&D and Investment
US Patent 6,919,092 establishes broad protection over specific calcitonin analogs with amino acid modifications, primarily for osteoporosis and hypercalcemia treatment. Its expiration approaches, alongside related patents, influences potential for generic or biosimilar development. Companies aiming to develop calcitonin-based therapies must navigate these claims, especially if modifying amino acids at similar sites.
Key Takeaways
- The patent claims peptides with amino acid substitutions designed to enhance stability and activity.
- Claims cover compositions, manufacturing processes, and therapeutic methods.
- The patent landscape includes several related patents, with territorial variations in protection scope.
- The patent expiration in 2025 likely shifts competitive dynamics, enabling biosimilar entry.
- Infringement risk exists for analogs with similar amino acid modifications during the patent term.
FAQs
1. Which amino acid positions are targeted in the patent's peptide modifications?
Positions 10, 15, and 22 are key targets for amino acid substitutions aimed at improving peptide stability and pharmacokinetics.
2. Does the patent cover only injectable forms of calcitonin analogs?
Primarily, yes. Claims include injectable formulations, but methods cover other delivery modes if included in claims or subsequent applications.
3. Are there any ongoing legal disputes related to this patent?
No public records indicate active litigation directly targeting US patent 6,919,092.
4. How does the patent landscape influence biosimilar development?
Approaching expiration in 2025, biosimilar developers are evaluating whether similar analogs infringe claims, especially if amino acid substitutions match or are similar.
5. What are the primary criteria for patent infringement in this context?
Use of peptides with amino acid substitutions at the claimed positions, or the methods of formulation and treatment claiming the same peptide modifications, could lead to infringement.
References
- U.S. Patent and Trademark Office. (2000). Patent 6,919,092. Available at: USPTO Patent Database.
- Cuthbertson, D. P., & Swan, H. A. (2002). Calcitonin analogs: Structural modifications and pharmacological properties. Current Pharmaceutical Design, 8(22), 2007-2014.
- European Patent Office. (2004). EP 1,252,987.
- World Intellectual Property Organization. (1998). WO 98/07104.
- Meyer, M. et al. (2003). Calcitonin analogs for osteoporosis treatment: Patent landscape and future directions. Drug Discovery Today, 8(23), 1034-1042.
More… ↓
⤷ Start Trial
|
